Abstract
Cimigenol ( 1) and 39 related compounds were screened as potential antitumor promoters by examining the ability of the compounds to inhibit Epstein–Barr virus early antigen (EBV-EA) activation (induced by 12- O-tetradecanoylphorbol-13-acetate) in Raji cells. Structure–activity relationship analysis indicated that compound 1 showed the highest activity and also exhibited significant inhibitory effects on mouse skin tumor promotion in an in vivo two-stage carcinogenesis test. These data suggest that 1 and the related compounds might be valuable anti-tumor promoters.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
